Treatment algorithms and the pharmacological management of type 2 diabetes

Diabetes Spectrum

Volumn 19, Issue 4, 2006, Pages 249-255

  Chitre, Mona M ^a   Burke, Susan ^a  

^a Blue Cross and Blue Shield Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; INSULIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ALGORITHM; CONGESTIVE HEART FAILURE; DIET THERAPY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 33845359799     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.19.4.249     Document Type: Review

References (19)

1. Chacra AR, Davidson JA, Diaz J, Escalante-Pulido M, Litwak LE, Mestman JH, More L, Violante RM: An algorithm for the treatment of type 2 diabetes in Latin America. Diabetes Obes Metab 7:148-160, 2005
2. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 352:837-853, 1998
3. U.K. Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet 352:854-865, 1998
4. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 28 (Suppl. 1):S4-S36, 2005
5. American Association of Clinical Endocrinologists: AACE diabetes guidelines. Endocr Pract 8 (Suppl. 1):40-82, 2002
6. Clement S: Guidelines for glycemic control. Clin Cornerstone 6:31-39, 2004
7. Nowak SN, Singh R, Clarke A, Campbell E, Jaber LA: Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic (Letter). Diabetes Care 25:1479, 2002
8. Fanning EL, Selwyn BJ, Larme AC, DeFronzo RA: Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population. Diabetes Care 27:1638-1646, 2004
9. Miller CD, Phillips LS, Tate MK, Porwoll JM, Rossman SD, Cronmiller N, Gebhart SS: Meeting American Diabetes Association Guidelines in endocrinologist practice. Diabetes Care 23:444-448, 2000
10. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J: Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 24:1411-1415, 2001
11. Bonora E, Formentini G, Calcaterra C, Lombard S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggee M: HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135-1141, 2002
12. Simonson D, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, DeFronzo RA: Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33:838-845, 1984
13. Best JD, Judzewitsch RG, Pfeifer MA, Beard JC, Halter JB, Porte D Jr: The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes 31:333-338, 1982
14. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
15. Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG: Constructing an algorithm for managing type 2 diabetes: focus on the role of the thiazolidinediones. Postgrad Med 8:63-72, 2003
16. Ovalle F, Bell DSH: Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 4:56-59, 2002
17. Ovalle F, Bell DSH: Thiazolidinedione induced recovery of pancreatic beta cell function (Abstract). Diabetes 49 (Suppl. 1):A120, 2000
18. Schmitz O, Brock B, Rungby J: Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53:S233-S238, 2004
19. DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269, 1997